Articles

Pharmacovigilance

In-depth, citation-backed writing on pharmacovigilance. · 7 articles in Pharmacovigilance

Pharmacovigilance

What Serious Adverse Event Categories Have Been Reported After Compounded BPC-157 Injections — Immune Reactions, Liver Signals, Allergic Events, and Tumor-Growth Risk — in 2026?

As of 2026, serious adverse events reported after compounded BPC-157 injections span four clinical categories: immune-mediated reactions driven by peptide immunogenicity, allergic and anaphylactoid responses from parenteral exposure, hepatic signals that remain mechanistically unresolved, and a theoretical tumor-growth risk grounded in BPC-157's pro-angiogenic activity. No controlled human trial has characterised the incidence or causation of any category.

·11 min read
Pharmacovigilance

How Should Clinicians Assess Causality, Dose Uncertainty, and Product Quality When a Patient Reports an Adverse Event After Non-Approved BPC-157 Use in 2026?

When a patient presents with a suspected adverse event after non-approved BPC-157 use in 2026, clinicians face three compounding uncertainties: causality cannot be established through standard dechallenge-rechallenge logic, the administered dose is unverifiable, and the product may contain immunogenic impurities unrelated to BPC-157's intrinsic pharmacology. Structured causality tools, dose reconstruction, and product-quality interrogation are the three assessment pillars.

·11 min read
Pharmacovigilance

When Ten Serious Adverse Events Exist but Zero Controlled Human Efficacy Trials Do, What Does the BPC-157 Evidence Record Actually Tell Us in 2026?

As of 2026, the BPC-157 evidence record presents a structural asymmetry: ten serious adverse event reports filed with the FDA's Adverse Event Monitoring System since 2021 — eight of them in 2026 alone — exist alongside zero completed, peer-reviewed, randomised controlled human efficacy trials. That asymmetry fundamentally limits what either dataset can be interpreted to mean.

·11 min read
Pharmacovigilance

Are Glutathione Injections and IV Infusions Linked to Contaminated-Product Illnesses in 2026?

Yes. A 2026 CDC multistate investigation confirmed more than 25 illnesses, including hospitalizations, linked to compounded injectable glutathione with elevated bacterial endotoxin. Four Texas compounding pharmacies issued nationwide recalls between August and October 2026. The root cause was dietary supplement-grade glutathione used as a starting ingredient, which does not meet sterility or endotoxin standards for injectable drug manufacturing.

·10 min read
Pharmacovigilance

What Is the Current Human Safety Signal for BPC-157 in Unapproved Injection Products in 2026?

As of September 2026, the human safety signal for BPC-157 in unapproved injection products is escalating but incompletely characterised. A real-world pharmacovigilance preprint documented a 33-fold rise in confirmed users between 2020 and 2026. The FDA's Adverse Event Monitoring System recorded 10 serious adverse event reports since 2021, with 8 filed in 2026 alone. BPC-157 holds no FDA approval.

·10 min read
Pharmacovigilance

What Safety Signals Has MK-677 (Ibutamoren) Produced in Human Trials, and How Serious Is the Congestive Heart Failure Risk in 2026?

Ibutamoren mesylate has produced clinically significant safety signals in human trials. The most serious is congestive heart failure and a trial was terminated early after CHF occurred in six-point-five percent of treated elderly patients versus one-point-six percent on placebo. Ibutamoren carries no FDA approval as of 2026.

·9 min read
Pharmacovigilance

Do GLP-1 Receptor Agonists Increase the Risk of Clinically Recorded Hair Loss Compared With Other Diabetes Drug Classes in 2026?

A 2024 BMJ target-trial emulation using Penn Medicine electronic health records found that GLP-1 receptor agonist initiators had a statistically significant higher incidence of clinically recorded alopecia than users of DPP-4 inhibitors or SGLT-2 inhibitors, with an adjusted hazard ratio of approximately 1.33 versus DPP-4 inhibitors after propensity-score weighting.

·9 min read